On Monday, Microsoft Corporation (NASDAQ:MSFT)’s shares inclined 0.50% to $55.95. With its recent share price change, MSFT market value has reached roughly $444.69 billion. Its most recent quarter balance sheet showed the company is standing at a 2.50 current ratio and possess 0.50 as debt to equity ratio. The company has a Profit Margin (ttm) of 13.50% and has 64.80% gross margins. The operating profit margin is 19.70%. The stock’s performance in 1 month is 4.21% and its volatility for the same period is 1.48%.
Microsoft Corporation, a technology company, develops, licenses, and supports software products, services, and devices worldwide. The company’s Devices and Consumer (D&C) Licensing segment licenses Windows operating system and related software; Microsoft Office for consumers; and Windows Phone operating system. Its Computing and Gaming Hardware segment provides Xbox gaming and entertainment consoles and accessories, second-party and third-party video games, and Xbox Live subscriptions; surface devices and accessories; and Microsoft PC accessories.
Weatherford International Plc (NYSE:WFT)’s shares dropped -2.81% to $8.64. The market capitalization of Weatherford International Plc (NYSE:WFT) is $6.93 billion. Turning to market valuation, the Price-to-Sales ratio is 0.60 and the Price-to-Book ratio is finally 1.18. The beta ratio has a value of 2.23.
Weatherford International plc provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Adamas Pharmaceuticals Inc (NASDAQ:ADMS)‘s shares dipped -1.77% to $29.43.
Adamas Pharmaceuticals, Inc. (ADMS) declared that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease met its primary endpoint. Results from this randomized, placebo-controlled study showed a statistically noteworthyreduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 as contrast to placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS). This represents a 23 percent reduction in LID for ADS-5102-treated patients contrast to placebo. The reduction in LID was maintained at 24 weeks (p = 0.0008), a key secondary analysis. The company plans to present comprehensive data at an forthcoming scientific conference.
“We are very happy with these top-line results that confirm and extend the positive findings from our earlier randomized, placebo-controlled study,” stated Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “Parkinson’s disease patients have no approved medicine for this potentially serious complication of levodopa therapy. With these data in hand, we look forward to talking with the FDA about our planned NDA submission for ADS-5102.”
In this study, there were four additional key secondary analyses based on patient diary data. All achieved statistical significance. Notably, at week 12, ADS-5102 significantly raised ON time without troublesome dyskinesia by 2.7 hours as contrast to placebo and reduced OFF time by 0.9 hours. These effects were maintained at week 24.
Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.